TCL.AU

13.68

-0.8%↓

COL.AU

23.27

+0.13%↑

QAN.AU

10.99

+1.2%↑

CAR.AU

36.91

-0.89%↓

WOR.AU

-0.57%↓

TCL.AU

13.68

-0.8%↓

COL.AU

23.27

+0.13%↑

QAN.AU

10.99

+1.2%↑

CAR.AU

36.91

-0.89%↓

WOR.AU

-0.57%↓

TCL.AU

13.68

-0.8%↓

COL.AU

23.27

+0.13%↑

QAN.AU

10.99

+1.2%↑

CAR.AU

36.91

-0.89%↓

WOR.AU

-0.57%↓

TCL.AU

13.68

-0.8%↓

COL.AU

23.27

+0.13%↑

QAN.AU

10.99

+1.2%↑

CAR.AU

36.91

-0.89%↓

WOR.AU

-0.57%↓

TCL.AU

13.68

-0.8%↓

COL.AU

23.27

+0.13%↑

QAN.AU

10.99

+1.2%↑

CAR.AU

36.91

-0.89%↓

WOR.AU

-0.57%↓

Strona główna・Stock List・CSL Ltd

CSL Ltd

Closed

SectorIndustrials

194.68 -1.52

Buy Sell

Overview

Share price change

24h

Current

Min

194.46

Max

195.66

Key metrics
By Trading Economics
Income	2B
Sales	-5.7B 2.5B
P/E Sector Avg	21.317 39.3
EPS	2.04
Dividend yield	1.47
Profit margin	24.437
Employees	29,904
EBITDA	-2.4B 858M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+42.16% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.47% 2.33%

Market Stats
By TradingEconomics
Market Cap	-28B 97B
Previous open	196.2
Previous close	194.68

News Sentiment

By Acuity

60%

40%

401 / 457 Ranking in Industrials

CSL Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 wrz 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

19 sie 2025, 03:32 UTC

Major Market Movers

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18 sie 2025, 23:46 UTC

Earnings

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18 sie 2025, 22:15 UTC

Earnings

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9 kwi 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 lut 2025, 21:55 UTC

Earnings

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 wrz 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

18 sie 2025, 23:46 UTC

Market Talk

Earnings

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18 sie 2025, 21:52 UTC

Earnings

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18 sie 2025, 21:51 UTC

Earnings

CSL to Cut Up to 15% of Staff>CSL.AU

18 sie 2025, 21:49 UTC

Earnings

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18 sie 2025, 21:49 UTC

Earnings

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18 sie 2025, 21:48 UTC

Earnings

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18 sie 2025, 21:47 UTC

Earnings

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18 sie 2025, 21:46 UTC

Earnings

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18 sie 2025, 21:45 UTC

Earnings

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18 sie 2025, 21:45 UTC

Earnings

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18 sie 2025, 21:44 UTC

Earnings

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18 sie 2025, 21:43 UTC

Earnings

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18 sie 2025, 21:43 UTC

Earnings

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18 sie 2025, 21:42 UTC

Earnings

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18 sie 2025, 21:42 UTC

Earnings

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17 cze 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 kwi 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 mar 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 lut 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

Peer Comparison

Price change

CSL Ltd Forecast

Price Target

By TipRanks

42.16% upside

12 Months Forecast

Average 276.116 AUD 42.16%

High 300 AUD

Low 227.5 AUD

Based on 12 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to CSL Ltd - Dist in the past 3 months.

Sentiment

By Acuity

401 / 457 Ranking in Industrials

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.